Literature DB >> 8723488

In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs.

M Viora1, A De Luca, A D'Ambrosio, A Antinori, E Ortona.   

Abstract

The anti-Pneumocystis carinii drug effects on mitogen-, antigen-, and interleukin-2-induced proliferative responses and on natural killer (NK) cell-mediated activity were analyzed in vivo (rats) and in vitro (normal human peripheral blood mononuclear cells). Splenocytes derived from in vivo piritrexim- and clindamycin-treated rats showed a significant inhibition of mitogen-induced proliferative responses. In vitro exposure to clindamycin, piritrexim, and pyrimethamine caused an inhibition of human T lymphocyte proliferation in response to mitogen, antigen, and interleukin-2 stimulation. Rat NK cell-mediated cytotoxic activity was not affected by the drugs, and human NK cell activity was reduced only at the highest concentration (10 micrograms/ml) of the drugs. The potential immunotoxicity of the long-term administration of these agents in humans needs further investigation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723488      PMCID: PMC163313          DOI: 10.1128/AAC.40.5.1294

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.

Authors:  S F Queener; M S Bartlett; M A Jay; M M Durkin; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Authors:  C Leport; F Raffi; S Matheron; C Katlama; B Regnier; A G Saimot; C Marche; C Vedrenne; J L Vilde
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965

3.  An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis.

Authors:  C Leport; S Bastuji-Garin; C Perronne; D Salmon; C Marche; F Briçaire; J L Vilde
Journal:  J Infect Dis       Date:  1989-09       Impact factor: 5.226

4.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

Authors:  K T Brunner; J Mauel; J C Cerottini; B Chapuis
Journal:  Immunology       Date:  1968-02       Impact factor: 7.397

5.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

6.  Paradoxical effect of BW 301U, a lipophilic antifolate, on methotrexate-inhibitable deoxyuridine incorporation by human hematopoietic cells.

Authors:  H J Iland; J Laszlo; W D Sedwick
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

7.  Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; B L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

8.  Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J M Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

9.  Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.

Authors:  J A Kovacs; C J Allegra; S Kennedy; J C Swan; J Drake; J E Parrillo; B Chabner; H Masur
Journal:  Am J Trop Med Hyg       Date:  1988-11       Impact factor: 2.345

10.  Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent.

Authors:  C J Allegra; J A Kovacs; J C Drake; J C Swan; B A Chabner; H Masur
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

View more
  1 in total

1.  Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes.

Authors:  Jae-Woo Jang; Yeonhwa Song; Kang Mo Kim; Jin-Sun Kim; Eun Kyung Choi; Joon Kim; Haengran Seo
Journal:  BMC Cancer       Date:  2016-10-18       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.